Crispr Therapeutics shares tumble after significant earnings miss
RA’ANANA, Israel - Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN), a developer of life-support and diagnostic technologies, disclosed today that it has received a notice from Nasdaq regarding non-compliance with the minimum bid price rule. The notification, dated March 10, 2025, indicates that the company’s stock has closed below the required $1.00 per share threshold for 30 consecutive business days. According to InvestingPro data, the stock is currently trading at $0.70, having declined over 24% year-to-date and showing particularly weak momentum in recent weeks.
The Nasdaq Listing Rule 5550(a)(2) sets the minimum bid price, and Inspira now has until September 8, 2025, to meet this requirement. The company must maintain a closing bid price of $1.00 or more for at least 10 consecutive business days within this 180-day period to regain compliance. With a market capitalization of just $17 million and an InvestingPro Financial Health Score rated as WEAK, the company faces significant challenges ahead.
If Inspira fails to comply by the deadline, it may be granted a second 180-day period to meet the criteria, provided it satisfies other initial listing standards for the Nasdaq Capital Market, except for the minimum bid price. During this time, the company may consider a reverse share split among other options to address the deficiency.
Inspira’s ordinary shares will continue to be listed and traded on the Nasdaq Capital Market throughout the compliance period. The company has stated its intention to monitor its share price closely and is exploring all available avenues to resolve the issue and comply with Nasdaq’s requirements.
The announcement comes as part of the company’s obligation under Nasdaq Listing Rule 5810(b) to promptly disclose the receipt of a deficiency notification. Inspira Technologies specializes in respiratory support and diagnostics, with products such as the INSPIRA ART system and HYLA blood sensor technology in various stages of development and regulatory approval. InvestingPro analysis reveals the company is quickly burning through cash, with negative EBITDA of $11.1 million in the last twelve months. Subscribers to InvestingPro can access 4 additional key insights about Inspira’s financial health and market position.
The information in this article is based on a press release statement from Inspira Technologies.
In other recent news, Inspira Technologies OXY B.H.N. Ltd. has announced promising initial results from its collaboration with Ennocure MedTech Ltd. The ex-vivo testing of their bio-electronic patch demonstrated a 95% reduction in bacterial presence within four hours on porcine skin models, with sustained effectiveness over a 24-hour period. This innovative technology employs physical electric stimulation to inhibit bacterial growth on treated surfaces, offering a non-chemical approach to infection prevention. The patch is designed to enhance traditional IV dressings by preventing bacterial growth, potentially extending wear time and providing real-time monitoring capabilities. The efficacy of the patch was confirmed against standardized antimicrobial performance protocols, including the AATCC TM100 standard. These developments are significant for the 250,000 patients who suffer from bloodstream infections related to intravenous lines each year. While the results are encouraging, it is important to note that the patch has not yet received regulatory approval. This information is based on a press release statement from Inspira Technologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.